Diclofenac Sodium And Misoprostol
NDC Package 10544-955-14
Package Information
Diclofenac Sodium And Misoprostol is carefully consider the potential benefits and risks of diclofenac sodium and misoprostol delayed-release tablets and other treatment options before deciding to use diclofenac sodium and misoprostol delayed-release tablets. Marketed by Blenheim Pharmacal, Inc., this product is identified by NDC 10544-955 and is authorized under FDA application ANDA200540.
Identification & Billing
- RxCUI: 1359105 - diclofenac sodium 75 MG / miSOPROStol 0.2 MG Delayed Release Oral Tablet
- RxCUI: 1359105 - diclofenac sodium 75 MG / misoprostol 0.2 MG Delayed Release Oral Tablet
- RxCUI: 1359105 - diclofenac sodium (enteric coated core) 75 MG / misoprostol (non-enteric coated mantle) 200 MCG Oral Tablet
- RxCUI: 1359105 - diclofenac sodium 75 MG / misoprostol 200 MCG Delayed Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 10544 - Blenheim Pharmacal, Inc.
- 10544-955 - Diclofenac Sodium And Misoprostol
- 10544-955-14 - 14 TABLET, DELAYED RELEASE in 1 BOTTLE
- 10544-955 - Diclofenac Sodium And Misoprostol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 10544-955-14 identifies a specific commercial package of 14 tablet, delayed release in 1 bottle of Diclofenac Sodium And Misoprostol Delayed-release, labeled by Blenheim Pharmacal, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Blenheim Pharmacal, Inc. on July 15, 2014. The current certification is valid through December 31, 2017.
How is this Blenheim Pharmacal, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 10544095514. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.